A Phase IIb, Open-Label, Randomized Study of LDOS47 in Combination with Vinorelbine/Cisplatin Versus Vinorelbine/Cisplatin Alone in Patients with Stage IV Lung Adenocarcinoma

Trial Profile

A Phase IIb, Open-Label, Randomized Study of LDOS47 in Combination with Vinorelbine/Cisplatin Versus Vinorelbine/Cisplatin Alone in Patients with Stage IV Lung Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs L-DOS 47 (Primary) ; Cisplatin; Vinorelbine
  • Indications Adenocarcinoma; Lung cancer
  • Focus Adverse reactions
  • Sponsors Helix BioPharma
  • Most Recent Events

    • 10 Apr 2018 According to a Helix BioPharma media release, the company has received regulatory and ethics approvals to dose the first patient in this trial in Ukraine. Enrollment in this study is expected to begin in May.
    • 19 Mar 2018 According to a Helix BioPharma media release, this study is in the early stage of set-up with expectation for patient enrolment sometime in the second calendar quarter of 2018 (Poland and Ukraine).
    • 05 Jan 2018 According to a Helix BioPharma media release, the clinical trial application of this trial is under review by regulatory agencies in Poland and Ukraine. Based on the Companys responses to initial set of inquiries, patient enrollment will start in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top